Abstract #3428

Detection of Metabolic Biomarkers of Response to BRAF and MEK Inhibitor Therapy of Melanoma

Pradeep Kumar Gupta¹, Stepan Orlovskiy¹, David S. Nelson¹, Stephen Pickup¹, Alexander A. Shestov¹, Fernando Arias-Mendoza¹, Mary E. Putt², Dennis B. Leeper³, Jerry D. Glickson¹, and Kavindra Nath¹

¹Department of Radiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States, ²Department of Biostatistics and Epidemiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States, ³Department of Radiation Oncology, Thomas Jefferson University, Philadelphia, PA, United States

Synopsis

In vivo ¹H and ³¹P MRS were used to monitor the effects of BRAF and MEK inhibitors therapy in two metabolically different melanoma xenograft models. Our approach is to combine BRAF inhibitor with MEK inhibitor in melanoma xenograft models. Combination of BRAF and MEK inhibitors has been shown to be more effective than the use of either drug alone. Differences in relative levels of glycolysis between two melanoma xenograft models may produce differential therapeutic responses to BRAF and MEK inhibitors . In melanoma, metabolic changes in response to targeted kinase inhibitor therapy occur rapidly and are related to subsequent tumor response.

How to access this content:

For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.

After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.

After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.

Click here for more information on becoming a member.